Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study

Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study

Background and Aims: Nivolumab was the first immune checkpoint inhibitor approved for hepatocellular carcinoma (HCC). External beam radiation therapy (EBRT) is locally effective and may enhance the effectiveness of immunotherapy. This study investigated the efficacy and safety of concurrent nivoluma...

Full description

Bibliographic Details
Main Authors: Bo Hyun Kim, Hee Chul Park, Tae Hyun Kim, Young-Hwan Koh, Jung Yong Hong, Yuri Cho, Dong Hyun Sinn, Boram Park, Joong-Won Park
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:JHEP Reports
Subjects:
hepatocellular carcinoma
nivolumab
radiotherapy
combination therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555923003221

Similar Items

Similar Items